Feature
Article
Pharmaceutical Executive
Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Follow the links below to read about each product:
Camzyos (Bristol Myers Squibb)
Enhertu (Daiichi Sankyo, AstraZeneca)
Rebyota (Ferring Pharmaceuticals)
Tzield (Provention Bio, a Sanofi company)
Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.